

Press release,
Paris, July 22, 2022

Keensight Capital invests in BYG4lab, a leading data management software for medical laboratories, to accelerate its international development

Keensight Capital, one of the leading private equity managers dedicated to pan-European Growth Buyout¹ investments, has acquired a majority stake in BYG4lab, a leading independent provider of data management software for medical laboratories specialized in both biology and microbiology.

Founded in 1982 and headquartered in France, BYG4lab (the “Company”) develops software that enhances the efficiency of a laboratory. The Company provides a number of key benefits, including but not limited to: improving workflow management, making instrument integration more efficient, handling mega lab configuration, designing personalized dashboards, maximizing automatic validation, and managing quality control. The Company addresses both Central Lab and Point of Care testing, as well as all disciplines in the field of medical biology – immunochemistry, hematology, molecular, microbiology, and, amongst others – serving 4,500+ individual laboratories, including some of the large, major European players.

BYG4lab is the clear European leader with one of the most comprehensive offerings, covering all disciplines of a laboratory, with the ability to connect to any kind of diagnostic equipment. It covers the entire software chain from license sale and implementation to maintenance and after-sales services. Its products provide best-in-class technological capabilities, including an outstanding user experience, which together have been made possible thanks to strong investments in R&D.

Since its acquisition by Cyril Verhille, the Company has grown to become a team of nearly 100 employees, of which c.40% work in R&D, while delivering an annual double-digit sales growth. It benefits from strong, favourable client recognition given its ability to deliver turnkey solutions, answering customers’ needs by increasing efficiency, delivering high quality outcomes, and driving cost effectiveness.

The Company has a proven business model in an attractive market that is poised for continued growth. Keensight Capital will support BYG4lab’s management team in its ambition to become the world leader in data management software for laboratories by expanding into new strategic areas in Europe and North America, tackling other sectors of activities, and further diversifying its offering and reach by developing new products and partnerships. These value creation levers will be achieved both organically and through acquisitions.

“Over the past 10 years, BYG4lab has become a leading player in its niche and is now ready to accelerate its growth by activating product diversification and geographic expansion. Keensight Capital’s investment is a significant signal of this new phase of our growth. Keensight team’s dual expertise in both Technology and Healthcare and its capacity to help us expand internationally will be great assets to bring the company to the next level,” said **Cyril Verhille CEO of BYG4lab**.

“We identified BYG4lab as a true international leading player in the Healthtech space and have been impressed by its unique position in a market with strong value creation potential. We are delighted to partner with Cyril and the seasoned management team to support them in the next phase of BYG4lab’s growth,” stated **Gregory Agez, Partner at Keensight Capital**.

¹ **Growth Buyout:** investment in profitable, private companies experiencing strong growth, through minority or majority positions with or without leverage, using a flexible approach tailored to the needs of individual entrepreneurs, in order to finance organic growth projects, acquisition strategies, or provide historic shareholders with liquidity.



About BYG4lab's

[Home - BYG4lab](#)

BYG4lab is a software company specialized in Data Management solutions in the healthcare industry. Available in 11 languages, the BYG4lab solutions are used by more than 4500 laboratories around the world. BYG4lab is the privileged partner of several companies in the IVD industry including instrument suppliers and both private and public laboratory networks. BYG4lab is ISO 13485: 2016 certified and follows the most demanding international recommendations in terms of the medical software development cycle (IEC 62304), cybersecurity and data privacy.

About Keensight Capital

www.keensightcapital.com

Keensight Capital, one of the leading European Growth Buyout firms, is committed to supporting entrepreneurs as they implement their growth strategies. For 20 years, Keensight Capital's team of seasoned professionals has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €10 million to €400 million. Drawing on its expertise in the Technology and Healthcare sectors, Keensight identifies the best investment opportunities in Europe and works closely with management teams to develop and achieve their strategic vision. Keensight Capital's success has earned it a Gold Award from the Private Equity Exchange & Awards each year for the last five consecutive years, and in particular, the Best European Growth Private Equity Fund.

Media Contacts

Keensight Capital

Tim Lee – tle@keensightcapital.com – +44 7785 345 250

Citigate Dewe Rogerson

Yoann Besse – yoann.besse@citigatedewerogerson.com – +33 6 63 03 84 91

Lea Schultz – lea.schultz@citigatedewerogerson.com – +33 7 57 52 06 05